SEARCH

SEARCH BY CITATION

References

  • ABOUNADER, R., VILLEMURE, J.G. & HAMEL, E. (1995). Characterization of neuropeptide Y (NPY) receptors in human cerebral arteries with selective agonists and the new Y1 antagonist BIBP 3226. Br. J. Pharmacol., 116, 22452250.
  • BARRACO, R.A., ERGENE, E., DUNBAR, J.C. & EL-RIDI, M.R. (1990). Cardiorespiratory response patterns elicited by microinjections of neuropeptide Y in the nucleus tractus solitarius. Brain Res. Bull., 24, 465485.
  • BERGDAHL, A., NILSSON, T., CATERA, L., NILSSON, L., SUN, X.Y., HEDNER, T., ERLINGE, D., VALDEMARSON, S. & EDVINSSON, D. (1996). Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y1 receptor. Eur. J. Pharmacol., 316, 5964.
  • BITRAN, M., DANIELS, A.J. & BORIC, M.P. (1997). GW1229, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstrictor effect on neuropeptide Y in the hamster microcirculation. Eur. J. Pharmacol., 319, 4347.
  • BLOMQVIST, A.G. & HERZOG, H. (1997). Y-receptor subtypes–how many more Trends Neurosci., 20, 294298.
  • BRADFORD, M.M. (1976). A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248254.
  • BURKHOFF, A., LINEMEYER, D.L. & SALON, J.A. (1998). Distribution of a novel hypothalamic neuropeptide Y receptor gene and it's absence in rat. Mol. Brain Res., 53, 311316.
  • CADIEUX, A., PHENG, L.H., ST-PIERRE, S., FOURNIER, A. & BENCHEKROUN, M.T. (1993). The rabbit saphenous vein: a tissue preparation specifically enriched in NPY-Y1 receptor subtype. Regul. Pept., 46, 557564.
  • CASTAN, I., VALET, P., VOISIN, T., QUIDEAU, N., LABURTHE, M. & LAFONTAN, M. (1992). Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes. Endocrinology, 131, 19701976.
  • CHAURASIA, C., MISSE, G., TESSEL, R. & DOUGHTY, M.B. (1994). Nonpeptide peptidomimetic antagonists of the neuropeptide Y receptor: benextramine analogs with selectivity for the peripheral Y2 receptor. J. Med. Chem., 37, 22422248.
  • CHEN, G. & VAN DEN POL, A.N. (1996). Multiple NPY receptors coexist in pre- and postsynaptic sites: inhibition of GABA release in isolated self-innervating SCN neurons. J. Neurosci., 16, 77117724.
  • COLMERS, W.F. (1990). Modulation of synaptic transmission in hippocampus by neuropeptide Y: presynaptic actions. Ann. N. Y. Acad. Sci., 611, 206218.
  • COLMERS, W.F. & BLEAKMAN, D. (1994). Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci., 17, 373379.
  • CRISCIONE, L., RIGOLLIER, P., BATZL-HARTMANN, C., RUEGER, H., STRICKER-KRONGRAD, A., WYSS, P., BRUNNER, L., WHITEBREAD, S., YAMAGUCHI, Y., GERALD, C., HEURICH, R.O., WALKER, M.W., CHIESI, M., SCHILLING, W., HOFBAUER, K.G. & LEVENS, N. (1998). Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest., 102, 21362145.
  • DANIELS, A.J., MATTHEWS, J.E., SLEPETIS, R.J., JANSEN, M., VIVEROS, O.H., TADEPALLI, A., HARRINGTON, W., HEYER, D., LANDAVAZO, A. & LEBAN, J.J. (1995a). High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U.S.A., 92, 90679071.
  • DANIELS, A.J., MATTHEWS, J.E., VIVEROS, O.H., LEBAN, J.J., CORY, M. & HEYER, D. (1995b). Structure-activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand-receptor binding. Mol. Pharmacol., 48, 425432.
  • DOODS, H., GAIDA, W., WIELAND, HA., DOLLINGER, H., SCHNORRENBERG, G., ESSER, F., ENGEL, W., EBERLEIN, W. & RUDOLF, K. (1999). BIIE0246: A selective and high affinity neuropeptide Y Y2 receptor antagonist. Eur. J. Pharmacol., 384, R3R5.
  • DOODS, H.N., WIELAND, H.A., ENGEL, W., EBERLEIN, W., WILLIM, K.D., ENTZEROTH, M., WIENEN, W. & RUDOLF, K. (1996). BIBP 3226, the first selective neuropeptide Y1 receptor antagonist: a review of its pharmacological properties. Regul. Pept., 65, 7177.
  • DOODS, H.N., WIENEN, W., ENTZEROTH, M., RUDOLF, K., EBERLEIN, W., ENGEL, W. & WIELAND, H.A. (1995). Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther., 275, 136142.
  • DUMONT, Y., CADIEUX, A., DOODS, H., FOURNIER, A. & QUIRION, R. (2000b). Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIBO3304 (Y1) and CGP71683A (Y5). Can. J. Physiol. Pharmacol., (In Press)
  • DUMONT, Y., CADIEUX, A., PHENG, L.H., FOURNIER, A., ST PIERRE, S. & QUIRION, R. (1994). Peptide YY derivatives as selective neuropeptide Y/peptide YY Y1 and Y2 agonists devoided of activity for the Y3 receptor sub-type. Mol. Brain Res., 26, 320324.
  • DUMONT, Y., FOURNIER, A. & QUIRION, R. (1998a). Expression and characterization of the neuropeptide Y Y5 receptor subtype in the rat brain. J. Neurosci., 18, 55655574.
  • DUMONT, Y., FOURNIER, A., ST-PIERRE, S. & QUIRION, R. (1995). Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3–36 36 as selective Y1 and Y2 radioligands. J. Pharmacol. Exp. Ther., 272, 673680.
  • DUMONT, Y., FOURNIER, A., ST-PIERRE, S. & QUIRION, R. (1996). Autoradiographic distribution of [125I][Leu31,Pro34]PYY, and [125I]PYY3–36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse, 22, 139158.
  • DUMONT, Y., JACQUES, D., BOUCHARD, P. & QUIRION, R. (1998b). Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol., 402, 372384.
  • DUMONT, Y., JACQUES, D., ST-PIERRE, J.A., TONG, Y., PARKER, R., HERZOG, H. & QUIRION, R. (2000a). Neuropeptide Y, peptide YY and pancreatic polypeptide receptor proteins and mRNAs in mammalian brains. In: Quirion, R., Hokfelt, T. & Borjklund, A. (eds). Handbook of Chemical Neuroanatomy. Elsevier Science Publishers: London. In Press.
  • DUMONT, Y., MARTEL, J.C., FOURNIER, A., ST-PIERRE, S. & QUIRION, R. (1992). Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol., 38, 125167.
  • DUMONT, Y. & QUIRION, R. (2000). [125I]GR231118: A high affinity radioligand to investigate neuropeptide Y Y1 and Y4 receptors. Br. J. Pharmacol., 129, 3746.
  • FLOOD, J.F., HERNANDEZ, E.N. & MORLEY, J.E. (1987). Modulation of memory processing by neuropeptide Y. Brain Res., 421, 280290.
  • FOREST, M., MARTEL, J.C., ST-PIERRE, S., QUIRION, R. & FOURNIER, A. (1990). Structural study of the N-terminal segment of neuropeptide tyrosine. J. Med. Chem., 33, 16151619.
  • FUHLENDORFF, J., GETHER, U., AAKERLUND, L., LANGELAND-JOHANSEN, N., THOGERSEN, H., MELBERG, S.G., OLSEN, U.B., THASTRUP, O. & SCHWARTZ, T.W. (1990). [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. U.S.A., 87, 182186.
  • GEHLERT, D.R. (1998). Multiple receptors for the pancreatic polypeptide (PP-fold) family: physiological implications. Proc. Soc. Exp. Biol. Med., 218, 722.
  • GEHLERT, D.R., BEAVERS, L.S., JOHNSON, D., GACKENHEIMER, S.L., SCHOBER, D.A. & GADSKI, R.A. (1996c). Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol. Pharmacol., 49, 224228.
  • GEHLERT, D.R., GACKENHEIMER, S.L., SCHOBER, D.A., BEAVERS, L., GADSKI, R., BURNETT, J.P., MAYNE, N., LUNDELL, I. & LARHAMMAR, D. (1996b). The neuropeptide Y Y1 receptor selective radioligand, [125I][Leu31,Pro34]peptide YY, is also a high affinity radioligand for human pancreatic polypeptide 1 receptors. Eur. J. Pharmacol., 318, 485490.
  • GEHLERT, D.R., SCHOBER, D.A., BEAVERS, L., GADSKI, R., HOFFMAN, J.A., SMILEY, D.L., CHANCE, R.E., LUNDELL, I. & LARHAMMAR, D. (1996a). Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol. Pharmacol., 50, 112118.
  • GERALD, C., WALKER, M.W., CRISCIONE, L., GUSTAFSON, E.L., BATZL-HARTMANN, C., SMITH, K.E., VAYSSE, P., DURKIN, M.M., LAZ, T.M., LINEMEYER, D.L., SCHAFFHAUSER, A.O., WHITEBREAD, S., HOFBAUER, K.G., TABER, R.I., BRANCHEK, T.A. & WEINSHANK, R.L. (1996). A receptor subtype involved in neuropeptide-Y-induced food intake. Nature, 382, 168171.
  • GERALD, C., WALKER, M.W., VAYSSE, P.J., HE, C., BRANCHEK, T.A. & WEINSHANK, R.L. (1995). Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem., 270, 2675826761.
  • GLAUM, S.R., MILLER, R.J., RHIM, H., MACLEAN, D., GEORGIC, L.M., MACKENZIE, R.G. & GRUNDEMAR, L. (1997). Characterization of Y3 receptor-mediated synaptic inhibition by chimeric neuropeptide Y-peptide YY peptides in the rat brainstem. Br. J. Pharmacol., 120, 481487.
  • GOLOMBEK, D.A., BIELLO, S.M., RENDON, R.A. & HARRINGTON, M.E. (1996). Neuropeptide Y phase shifts the circadian clock in vitro via a Y2 receptor. Neuroreport, 7, 13151319.
  • GREGOR, P., FENG, Y., DECARR, L.B., CORNFIELD, L.J. & MCCALEB, M.L. (1996). Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue. J. Biol. Chem., 271, 2777627781.
  • GROUZMANN, E., BUCLIN, T., MARTIRE, M., CANNIZZARO, C., DORNER, B., RAZANAME, A. & MUTTER, M. (1997). Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist. J. Biol. Chem., 272, 76997706.
  • GROUZMANN, E., BUCLIN, T., MARTIRE, M., CANNIZZARO, C., DORNER, B., RAZANAME, A. & MUTTER, M. (1998). Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist [Erratum]. J. Biol. Chem., 273, 7699.
  • GRUNDEMAR, L., WAHLESTEDT, C. & REIS, D.J. (1991). Neuropeptide Y acts at an atypical receptor to evoke cardiovascular depression and to inhibit glutamate responsiveness in the brainstem. J. Pharmacol. Exp. Ther., 258, 633638.
  • HEILIG, M., MCLEOD, S., BROT, M., HEINRICHS, S.C., MENZAGHI, F., KOOB, G.F. & BRITTON, K.T. (1993). Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology, 8, 357363.
  • HEILIG, M. & WIDERLOV, E. (1995). Neurobiology and clinical aspects of neuropeptide Y. Crit. Rev. Neurobiol., 9, 115136.
  • HIPSKIND, P.A., LOBB, K.L., NIXON, J.A., BRITTON, T.C., BRUNS, R.F., CATLOW, J., DIECKMAN-MCGINTY, D.K., GACKENHEIMER, S.L., GITTER, B.D., IYENGAR, S., SCHOBER, D.A., SIMMONS, R.M., SWANSON, S., ZARRINMAYEH, H., ZIMMERMAN, D.M. & GEHLERT, D.R. (1997). Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem., 40, 37123714.
  • HUHMAN, K.L., GILLESPIE, C.F., MARVEL, C.L. & ALBERS, H.E. (1996). Neuropeptide Y phase shifts circadian rhythms in vivo via a Y2 receptor. Neuroreport, 7, 12491252.
  • INUI, A. (1999). Neuropeptide Y feeding receptors: are multiple subtypes involved Trends Pharmacol. Sci., 20, 4346.
  • JACQUES, D., CADIEUX, A., DUMONT, Y. & QUIRION, R. (1995). Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Y1, Y2 and Y3 receptors. Eur. J. Pharmacol., 278, R3R5.
  • JACQUES, D., DUMONT, Y., FOURNIER, A. & QUIRION, R. (1997). Characterization of neuropeptide Y receptor subtypes in the normal human brain, including the hypothalamus. Neuroscience, 79, 129148.
  • JOLICOEUR, F.B., MICHAUD, J.N., MENARD, D. & FOURNIER, A. (1991b). In vivo structure activity study supports the existence of heterogeneous neuropeptide Y receptors. Brain Res. Bull., 26, 309311.
  • JOLICOEUR, F.B., MICHAUD, J.N., RIVEST, R., MENARD, D., GAUDIN, D., FOURNIER, A. & ST-PIERRE, S. (1991a). Neurobehavioral profile of neuropeptide Y. Brain Res. Bull., 26, 265268.
  • KALRA, S.P. & CROWLEY, W.R. (1984). Norepinephrine-like effects of neuropeptide Y on LH release in the rat. Life Sci., 35, 11731176.
  • KALRA, S.P. & CROWLEY, W.R. (1992). Neuropeptide Y: a novel neuroendocrine peptide in the control of pituitary hormone secretion, and its relation to luteinizing hormone. Front Neuroendocrinol., 13, 146.
  • KANATANI, A., FUKAMI, T., FUKURODA, T., IWAASA, H., MACNEIL, D.J. & VAN DER PLOEG, L.H. (1997). Y5 receptors are not involved in physiologically relevant feeding in rodents. Regul. Pept., 71, 212.
  • KANATANI, A., ITO, J., ISHIHARA, A., IWAASA, H., FUKURODA, T., FUKAMI, T., MACNEIL, D.J., VAN DER PLOEG, L.H. & IHARA, M. (1998). NPY-induced feeding involves the action of a Y1-like receptor in rodents. Regul. Pept., 75–76 409415.
  • KLAPSTEIN, G.J. & COLMERS, W.F. (1993). On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus, 3, 103111.
  • KLAPSTEIN, G.J. & COLMERS, W.F. (1997). Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J. Neurophysiol., 78, 16511661.
  • LABURTHE, M. (1990). Peptide YY and neuropeptide Y in the gut: availability, biological actions and receptors. Trends Endocrinol. Meta., 1, 168174.
  • LABURTHE, M., CHENUT, B., ROUYER-FESSARD, C., TATEMOTO, K., COUVINEAU, A., SERVIN, A. & AMIRANOFF, B. (1986). Interaction of peptide YY with rat intestinal epithelial plasma membranes: binding of the radioiodinated peptide. Endocrinology, 118, 19101917.
  • LARHAMMAR, D. (1996). Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept., 65, 165174.
  • LEBAN, J.J., HEYER, D., LANDAVAZO, A., MATTHEWS, J., AULABAUGH, A. & DANIELS, A.J. (1995). Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1- type receptor. J. Med. Chem., 38, 11501157.
  • LUNDBERG, J.M. & MODIN, A. (1995). Inhibition of sympathetic vasoconstriction in pigs in vivo by the neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br. J. Pharmacol., 116, 29712982.
  • LUNDBERG, J.M., MODIN, A. & MALMSTROM, R.E. (1996). Recent developments with neuropeptide Y receptor antagonists. Trends Pharmacol. Sci., 17, 301304.
  • MALMSTROM, R.E., BALMER, K.C. & LUNDBERG, J.M. (1997). The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo. Br. J. Pharmacol., 121, 595603.
  • MARTEL, J.C., FOURNIER, A., ST-PIERRE, S., DUMONT, Y., FOREST, M. & QUIRION, R. (1990). Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors. Mol. Pharmacol., 38, 494502.
  • MATSUMOTO, M., NOMURA, T., MOMOSE, K., IKEDA, Y., KONDOU, Y., AKIHO, H., TOGAMI, J., KIMURA, Y., OKADA, M. & YAMAGUCHI, T. (1996). Inactivation of a novel neuropeptide Y/peptide YY receptor gene in primate species. J. Biol. Chem., 271, 2721727220.
  • MCQUISTON, A.R. & COLMERS, W.F. (1996). Neuropeptide Y2 receptors inhibit the frequency of spontaneous but not miniature EPSCs in CA3 pyramidal cells of rat hippocampus. J. Neurophysiol., 76, 31593168.
  • MICHEL, M.C., BECK-SICKINGER, A., COX, H., DOODS, H.N., HERZOG, H., LARHAMMAR, D., QUIRION, R., SCHWARTZ, T. & WESTFALL, T. (1998). XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev., 50, 143150.
  • MODIN, A. (1994). Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide. Acta Physiol. Scand. Suppl., 622, 174.
  • MORLEY, J.E. & FLOOD, J.F. (1989). The effect of neuropeptide Y on drinking in mice. Brain Res., 494, 129137.
  • NARVAEZ, J.A., AGUIRRE, J.A. & FUXE, K. (1993). Subpicomolar amounts of NPY(13-36) injected into the nucleus tractus solitarius of the rat counteract the cardiovascular responses to L-glutamate. Neurosci. Lett., 151, 182186.
  • NAVEILHAN, P., HASSANI, H., CANALS, J.M., EKSTRAND, A.J., LAREFALK, A., CHHAJLANI, V., ARENAS, E., GEDDA, K., SVENSSON, L., THOREN, P. & ERNFORS, P. (1999). Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nature Med., 5, 11881193.
  • NILSSON, T., CANTERA, L. & EDVINSSON, L. (1996a). Presence of neuropeptide Y Y1 receptor mediating vasoconstriction in human cerebral arteries. Neurosci. Lett., 204, 145148.
  • NILSSON, T., YOU, J., SUN, X., HEDNER, T. & EDVINSSON, L. (1996b). Characterization of neuropeptide Y receptors mediating contraction, potentiation and inhibition of relaxation. Blood Press., 5, 164169.
  • PARKER, E.M., BABIJ, C.K., BALASUBRAMANIAM, A., BURRIER, R.E., GUZZI, M., HAMUD, F., MUKHOPADHYAY, G., RUDINSKI, M.S., TAO, Z., TICE, M., XIA, L., MULLINS, D.E. & SALISBURY, B.G. (1998). GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. Pharmacol., 349, 97105.
  • PHENG, L.H., FOURNIER, A., DUMONT, Y., QUIRION, R. & REGOLI, D. (1997). The dog saphenous vein: a sensitive and selective preparation for the Y2 receptor of neuropeptide Y. Eur. J. Pharmacol., 327, 163167.
  • PHENG, L.H., PERRON, A., QUIRION, R., CADIEUX, A., FAUCHERE, J.L., DUMONT, Y. & REGOLI, D. (1999). Neuropeptide Y-induced contraction is mediated by Y2 and Y4 receptors in the rat colon. Eur. J. Pharmacol., 374, 8591.
  • QIAN, J., COLMERS, W.F. & SAGGAU, P. (1997). Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J. Neurosci., 17, 81698177.
  • QUIRION, R., ROBITAILLE, Y., MARTIAL, J., CHABOT, J.G., LEMOINE, P., PILAPIL, C. & DALPE, M. (1988). Human brain receptor autoradiography using whole hemisphere sections: a general method that minimizes tissues artefacts. Synapse, 1, 446454.
  • RACCHI, H., SCHLIEM, A.J., DONOSO, M.V., RAHMER, A., ZUSIGA, A., GUZMAN, S., RUDOLF, K. & HUIDOBRO-TORO, J.P. (1996). Neuropeptide Y Y1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation. Eur. J. Pharmacol., 329, 7983.
  • RUDOLF, K., EBERLEIN, W., ENGEL, W., WIELAND, H.A., WILLIM, K.D., ENTZEROTH, M., WIENEN, W., BECK-SICKINGER, A.G. & DOODS, H.N. (1994). The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol., 271, R11R13.
  • SCHOBER, D.A., VAN ABBEMA, A.M., SMILEY, D.L., BRUNS, R.F. & GEHLERT, D.R. (1998). The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides, 19, 537542.
  • SCHWARTZ, T.W., FUHLENDORFF, J., KJEMS, L.L., KRISTENSEN, M.S., VERVELDE, M., O'HARE, M., KRSTENANSKY, J.L. & BJORNHOLM, B. (1990). Signal epitopes in the three-dimensional structure of neuropeptide Y. Interaction with Y1, Y2, and pancreatic polypeptide receptors. Ann. N.Y. Acad. Sci., 611, 3547.
  • SERRADEIL-LE, GALC., VALETTE, G., ROUBY, P.E., PELLET, A., OURY-DONAT, F., BROSSARD, G., LESPY, L., MARTY, E., NELIAT, G. & DE COINTET, P. (1995). SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett., 362, 192196.
  • SERVIN, A.L., ROUYER-FESSARD, C., BALASUBRAMANIAM, A., SAINT, P.S. & LABURTHE, M. (1989). Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide- stimulated adenosine 3′,5′-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors. Endocrinology, 124, 692700.
  • STANLEY, B.G. & LEIBOWITZ, S.F. (1984). Neuropeptide Y: stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci., 35, 26352642.
  • TONG, Y., DUMONT, Y., SHEN, S.H., HERZOG, H., SHINE, J. & QUIRION, R. (1995). Expression of the neuropeptide Y Y1 receptor in human embryonic kidney 293 cells: ligand binding characteristics, in situ hybridization and receptor autoradiography. Mol. Brain Res., 34, 303308.
  • TOUGH, I.R. & COX, H.M. (1996). Selective inhibition of neuropeptide Y Y1 receptors by BIBP3226 in rat and human epithelial preparations. Eur. J. Pharmacol., 310, 5560.
  • VEZZANI, A., SPERK, G. & COLMERS, W.F. (1999). Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci., 22, 2530.
  • WAHLESTEDT, C. & REIS, D.J. (1993). Neuropeptide Y-related peptides and their receptors–are the receptors potential therapeutic drug targets Annu. Rev. Pharmacol. Toxicol., 33, 309352.
  • WAHLESTEDT, C., YANAIHARA, N. & HAKANSON, R. (1986). Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides. Regul. Pept., 13, 307318.
  • WIELAND, H.A., ENGEL, W., EBERLEIN, W., RUDOLF, K. & DOODS, H.N. (1998). Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J, Pharmacol., 125, 549555.
  • WIELAND, H.A., WILLIM, K. & DOODS, H.N. (1995). Receptor binding profiles of NPY analogues and fragments in different tissues and cell lines. Peptides, 16, 13891394.
  • WOLDBYE, D.P. (1998). Antiepileptic effects of NPY on pentylenetetrazole seizures. Regul. Pept., 75–76 279282.
  • WOLDBYE, D.P., LARSEN, P.J., MIKKELSEN, J.D., KLEMP, K., MADSEN, T.M. & BOLWIG, T.G. (1997). Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5- like receptors. Nat. Med., 3, 761764.
  • ZUKOWSKA-GROJEC, Z., DAYAO, E.K., KARWATOWASKA-PROKOPCZUK, E., HAUSER, G.J. & DOODS, H.N. (1996). Stress-induced mesenteric vasoconstriction in rats is mediated by neuropeptide Y Y1 receptors. Am,. J. Physiol., 270, H796H800.